-+ 0.00%
-+ 0.00%
-+ 0.00%

LIXTE BIOTECHNOLOGY HOLDINGS HIGHLIGHTS Q4 2025 PRIORITIES, INCLUDING ONGOING ADVANCEMENT OF LEAD CANDIDATE LB-100, STRATEGIC ONCOLOGY BUSINESS DEVELOPMENT AND ACQUISITION PLANS

Reuters·10/16/2025 12:00:04

Please log in to view news